Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the digestive tract ([@bib26]). Most GISTs harbour activating mutations of the gene encoding *KIT* or platelet-derived growth factor receptor (PDGFR) *α*, resulting in the constitutive activation of protein tyrosine kinase signalling ([@bib21]). Imatinib has improved survival outcomes dramatically and has become the standard first-line treatment for advanced GISTs ([@bib10]; [@bib5]). Patients who become resistant to imatinib are treated with second-line sunitinib ([@bib9]). Eventually, however, most patients become resistant to both imatinib and sunitinib, necessitating new salvage treatments ([@bib14]). Although many new targeted agents have been studied in patients with advanced GISTs ([@bib7]), at the time of study initiation, no therapeutic option after failure of both imatinib and sunitinib had been approved ([@bib12]; [@bib19]; [@bib25]).

Dovitinib (TKI258) is a novel multikinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) 1--3, fibroblast growth factor receptors (FGFRs) 1--3, fetal liver tyrosine kinase receptor 3, PDGFR *β*, and KIT ([@bib22]). Dovitinib showed potent antitumour activity in various tumour xenograft models ([@bib22]). Furthermore, a phase I trial of dovitinib in a cohort that included two patients with GISTs resulted in disease control for 8 months in one patient, where both imatinib and sorafenib failed ([@bib31]). Based on these findings and the target profile of dovitinib, we conducted a phase II trial evaluating the efficacy and safety of dovitinib in patients with GISTs refractory or intolerant to both imatinib and sunitinib.

Materials and methods
=====================

This was an open-label, single-arm, phase II study. The protocol was approved by the institutional review board of Asan Medical Center, Seoul, Korea, and all patients provided written informed consent before enrolment. This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

Eligibility
-----------

Patients with histologically and molecularly confirmed metastatic and/or unresectable GIST were considered eligible. Inclusion criteria included the following: age ⩾20 years; resistance and/or intolerance to both imatinib and sunitinib (previous use of other tyrosine kinase inhibitors (TKIs) or chemotherapy was permitted); an Eastern Cooperative Oncology Group (ECOG) performance status of 0--2; resolution of all toxicities of prior treatments to grade 0--1 per Common Terminology Criteria for Adverse Events (CTCAE) 3.0; measurable lesion per RECIST 1.0 ([@bib33]); and adequate bone marrow, hepatic, and renal function. Patients were also required to have a life expectancy of ⩾12 weeks, with study entry preceded by a washout period of previous TKIs for more than four times the half-life. Except for sunitinib and regorafenib, patients who received other TKIs targeting VEGFR or FGFR were not permitted to enrol. Patients were excluded if they had a serious medical condition that was clinically significant or required active intervention.

Study treatment
---------------

Dovitinib was administered at 500 mg orally once daily for 5 consecutive days, followed by a 2-day rest, with each cycle consisting of 28 days ([@bib2]). Study treatment was discontinued if patients had disease progression, unacceptable toxicities, or withdrew consent. Doses were modified based on the worst grade of toxicity according to the protocol, but doses less than 300 mg per day were not allowed. Patients who interrupted treatment for more than 21 days were discontinued.

Efficacy and safety assessment
------------------------------

Baseline assessments included medical history, physical examination, complete blood count, serum chemistry with electrolytes, coagulation battery, urinalysis, electrocardiography, cardiac enzymes, chest X-ray, computed tomography (CT) scan, and fusion 18-fluorodeoxyglucose (FDG)--positron emission tomography (PET)--CT scan. Computed tomography scans were performed after 4 and 8 weeks of treatment and every 8 weeks thereafter. Response was assessed by investigators using RECIST 1.0 ([@bib33]). To assess metabolic responses, PET--CT scans were performed at baseline and after 4 weeks of treatment. Maximum standardised uptake values (SUV~max~) of all tumour lesions were combined and averaged (average SUV~max~) for each patient. Metabolic response was defined based on the PET response criteria of the European Organization for Research and Treatment of Cancer (EORTC) ([@bib38]); a metabolic partial response (mPR) was defined as a \>25% reduction in average SUV~max~; metabolic stable disease (mSD) between a 25% decrease and 25% increase in average SUV~max~; metabolic progressive disease (mPD) as a ⩾25% increase in average SUV~max~ or the appearance of new FDG uptake in metastatic lesions. Toxicity was graded by CTCAE 3.0.

Pharmacokinetic evaluation
--------------------------

Blood samples were collected 1, 3, 6, and 24 h following the 500 mg oral dose of dovitinib on Week 1, Day 1, and before dosing and 1, 3, 6, and 24 h after dosing on Week 4, Day 5. The plasma concentrations of dovitinib were measured by liquid chromatography--tandem mass spectrometry, and analysed using Phoenix software (Pharsight Inc., Mountain View, CA, USA) to determine pharmacokinetic parameters including area under the concentration--time curve (AUC), time (*T*~max~) to reach the maximum plasma concentration (*C*~max~), and trough plasma concentration (*C*~min~).

Statistical analysis
--------------------

The primary endpoint of this study was disease control rate (DCR), defined as the proportion of patients showing an objective response and stable disease (SD), at 24 weeks of study treatment. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and overall response rate by CT or PET--CT scan.

Based on the Fleming rule, this study was designed to detect an improvement in DCR at 24 weeks of 20% from a null rate of 6% with type I (one-sided) and II errors of 10%. Assuming that 20% of patients were lost to follow-up, a total of 30 patients were required. If four or more patients achieved DCR at 24 weeks, the null hypothesis would be rejected with a target error rate of 10%.

Progression-free survival was defined as the time from the date of first dose to the date of disease progression or death, whichever occurred first. The OS was defined from the date of first dose to the date of death. The probability of survival was estimated by the Kaplan--Meier method, and the log-rank test was used to compare survival curves. A *P*-value \<0.05 was considered statistically significant, and all analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

Between September 2011 and April 2012, a total of 30 patients with metastatic and/or unresectable GISTs who had treatment failure with imatinib and sunitinib were enroled. Baseline patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. Median age was 57.5 years (range, 35--76 years) and 21 (70%) patients were male. All patients had distant metastases. Median number of prior TKI regimens was two (range, 2--5); 13 patients (43%) received and had treatment failure with nilotinib (27%), regorafenib (7%), or both (10%) before dovitinib treatment. *KIT* exon 11 and 9 mutations were detected in 20 (71%) and 5 (18%) patients, respectively. Resistance to imatinib and sunitinib per RECIST criteria was documented in all and 28 (93%) patients, respectively; the remaining two patients were intolerant to sunitinib.

Efficacy
--------

DCR at 24 weeks, the primary end point, was 13% (95% confidence interval (CI), 4.7--30.3%). At Week 24 of dovitinib treatment, 4 patients had disease stabilisation, 23 had disease progression or were dead, and 3 were not available for assessment: 2 due to early loss to follow-up and 1 due to patient refusal. According to RECIST criteria, 1 patient (3%) achieved partial response (PR), resulting in an objective response rate of 3%, 21 (70%) had SD for at least 8 weeks, and 6 (20%) showed progressive disease (PD), whereas 2 (7%) were not evaluable owing to the early loss to follow-up ([Table 2](#tbl2){ref-type="table"}). Median change from baseline in the sum of longest tumour diameters was 7% (interquartile range (IQR), −5--18% [Figure 1A](#fig1){ref-type="fig"}). Eight patients experienced a decrease in tumour diameter with a median of −11% (IQR, −16% to −7%).

Of the 28 patients whose metabolic responses were assessable, 4 (13%) achieved mPR, 15 (50%) achieved mSD, and 9 (30%) had mPD. After 4 weeks of treatment with dovitinib, the median change in average SUV~max~ was −3% from baseline (IQR, −16--36%), with 14 patients (47%) showing a decrease in average SUV~max~ of a median −15% (IQR, −38% to −11% [Figure 1B](#fig1){ref-type="fig"}).

[Figure 2](#fig2){ref-type="fig"} shows the CT and PET--CT scan images of a patient who achieved PR and mPR with dovitinib. This patient had a *KIT* exon 9 mutation and received dovitinib after progression on 12 months of imatinib and 3.5 months of sunitinib. Tumour SUV was substantially reduced at 4 weeks in PET--CT scan, indicating mPR, and PR according to RECIST criteria was confirmed after 28 weeks of treatment. At the time of analysis, this patient had received dovitinib without progression for approximately 11 months.

At a median follow-up of 8.3 months (range, 6.3--12.2 months), the median PFS was 3.6 months (95% CI, 3.5--3.7 months) and the 6-month PFS rate was 13% ([Figure 3](#fig3){ref-type="fig"}). The median OS was 9.7 months (95% CI, 6.0--13.4 months). Subgroup analyses showed that median PFS was significantly worse in patients with mPD after 4 weeks of dovitinib than in patients with mPR or mSD (2.8 months (95% CI, 0.7--4.9 months) *vs* 4.2 months (95% CI, 2.5--5.9), hazard ratio 2.7 (95% CI, 1.1--6.6); *P*=0.03), despite there being no significant between-group differences in baseline characteristics. Progression-free survival did not differ by primary genotype (*KIT* exon 11 mutations *vs* other mutations, *P*=0.71), age (\<60 *vs* ⩾60, *P*=0.77), sex (*P*=0.21), ECOG performance status (0--1 *vs* 2, *P*=0.50), number of prior TKI regimens (2 *vs* ⩾3, *P*=0.88), previous treatment with nilotinib (*P*=0.96) or regorafenib (*P*=0.10), and the best response (CR/PR *vs* SD/PD) and time to progression (\<median *vs* ⩾median) to previous imatinib (*P*=0.68 and *P*=0.26, respectively) or sunitinib (*P*=0.80 and *P*=0.32, respectively) treatment.

Safety
------

The most common adverse events (AEs) of any grade were diarrhoea (63%), nausea (60%), asthenia (60%), elevated alanine aminotransferase (50%), and anaemia (50%). These AEs were generally mild and tolerable. Grade 3/4 AEs included asthenia (20%), neutropenia (13%), thrombocytopenia (10%), and hypertriglyceridaemia (10%), with most cases being manageable by dose modification. There were no treatment-related deaths. [Table 3](#tbl3){ref-type="table"} summarises AEs occurring in 10% or more patients. Dovitinib was discontinued owing to toxicity in two patients: one for grade 3 QTc prolongation after four cycles, and the other one for grade 3 asthenia after five cycles. One patient experienced life-threatening severe AEs, including grade 3 left ventricular dysfunction, grade 4 thrombocytopenia, and grade 3 QTc prolongation. In total, 7 of 30 (23%) patients required dose reductions based on protocol-defined toxicities, with doses reduced to 300 mg per day in three patients (10%). Reasons for dose reduction included neutropenia (*n*=3), thrombocytopenia (*n*=2), vomiting (*n*=1), and hypertriglyceridaemia (*n*=1). There was one patient whose dose reduced to 400 mg per day due to grade 3 neutropenia, but tolerated subsequent re-escalation to 500 mg per day.

Pharmacokinetics
----------------

Dovitinib pharmacokinetics was evaluated in 14 patients, 11 males, and three females, of mean body weight 62 kg, with 10 having mild to moderate renal dysfunction. Pharmacokinetic parameters and plasma concentration--time profiles are shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}, respectively. The mean *C*~max~ and AUC of dovitinib were 194±51 ng ml^−1^ and 3444±847 h\*ng ml^−1^, respectively, on Week 1, Day 1 and were 232±84 ng ml^−1^ and 4396±1712 h\*ng ml^−1^, respectively, on Week 4, Day 5. Large interindividual variability (CV%) was observed in the parameters. There were no relationships between AUC and covariates, such as age (*P*=0.72), sex (*P*=0.36), body weight (*P*=0.36), body surface area (*P*=0.46), and estimated glomerular filtration rate (*P*=0.32).

Discussion
==========

In this phase II study, we investigated the efficacy and safety of dovitinib in patients with advanced GISTs. Dovitinib was well tolerated and showed modest antitumour activity in these heavily pretreated patients. This study met the prespecified primary end point of a DCR of 13% over 24 weeks, although only one (3%) patient achieved PR according to RECIST. The median PFS and OS were 3.6 and 9.7 months, respectively. Furthermore, treatment with dovitinib reduced the metabolic activity of GISTs in ∼47% of patients, with 13% of patients achieving mPR. As about half of our patients received dovitinib as fourth- or fifth-line therapy, these results suggest that dovitinib is clinically active in patients with GIST.

Imatinib has revolutionised the treatment of advanced GISTs ([@bib10]; [@bib5]). However, most patients develop resistance to and clinical progression on imatinib due to the development of secondary KIT mutations ([@bib3]; [@bib15]; [@bib14]). Most of these acquired mutations occur in the regions of the KIT gene that encode the ATP/drug-binding pocket (exons 13 and 14) and the activation loop (exon 17) ([@bib3]; [@bib15]; [@bib36]). Sunitinib is approved as the second-line therapy for GISTs after failure of imatinib, with a median PFS of about 7 months in a phase III trial ([@bib9]). Sunitinib potently inhibits imatinib-resistant *KIT* exon 13 and 14 mutations, but has little activity against imatinib-resistant *KIT* exon 17 mutations ([@bib16]; [@bib27]; [@bib17]). Although sunitinib inhibits VEGFR as well as KIT and PDGFR, it is still unclear whether VEGFR inhibition contributed to the activity of sunitinib against imatinib-resistant GISTs ([@bib17]).

Because patients eventually progress on imatinib and sunitinib, and their prognosis is generally poor, many targeted agents have been investigated in this setting, including nilotinib ([@bib24]; [@bib20]; [@bib32]; [@bib30]), sorafenib ([@bib37]; [@bib23]; [@bib28]), regorafenib ([@bib13]; [@bib8]), vatalanib ([@bib18]), dasatinib ([@bib34]), IPI-504 ([@bib6]), and BIIB021 ([@bib11]). Nilotinib has a chemical structure and target profile similar to imatinib and has been widely investigated in patients with GISTs ([@bib24]; [@bib20]; [@bib32]; [@bib30]). In a recent phase III trial for patients with prior failure of at least imatinib and sunitinib, nilotinib achieved a median PFS of 3.6 months and a DCR at 24 weeks of 7.3% and, when the efficacy of nilotinib was compared with control arm in true third-line patient population with exclusion of patients who received more than two prior agents and those without well-documented progression on second-line therapy, nilotinib provided significantly longer OS. However, it failed to demonstrate a significant improvement in survival in the intention-to-treat population ([@bib30]). Sorafenib, a multikinase inhibitor that blocks KIT, PDGFR, and VEGFR, showed promising activity as salvage therapy after failure of standard regimens for GIST patients with median PFS of 4.6--6.4 months in previous phase II and retrospective studies ([@bib37]; [@bib23]; [@bib28]) and DCR at 24 weeks, presented in a phase II study ([@bib28]), was 36%. Regorafenib is a highly related compound of sorafenib, with a similar target profile. Based on the promising activity, DCR at 16 weeks of 79% and median PFS of 10.0 months, in a phase II trial ([@bib13]), regorafenib was compared with placebo as third-line therapy in a randomised phase III trial ([@bib8]). Regorafenib enhanced median PFS relative to placebo (4.8 *vs* 0.9 months), with a 12-week DCR in the regorafenib group 53%, although objective responses were rarely observed ([@bib8]). Regorafenib is therefore approved as third-line treatment, following failures of imatinib and sunitinib, in patients with GISTs. Regorafenib and sorafenib may act in imatinib/sunitinib-resistant GISTs by potently inhibiting imatinib-resistant secondary KIT mutations involving the activation loop as these mutations are generally resistant to sunitinib ([@bib16]; [@bib27]; [@bib13]; [@bib17]). Because the mechanisms of resistance to TKIs in GISTs are heterogeneous and multiple acquired mutations can occur in a single patient ([@bib36]), KIT kinase inhibitors may have limited effectiveness in GISTs highly refractory to TKIs, with the activity of each inhibitor depending on the sensitivity to specific mutations. Therefore, inhibiting HSP90 has been considered a novel strategy to overcome this obstacle. Although several HSP90 inhibitors have been tested in clinical trials, further investigations are necessary to establish the role of HSP90 inhibition in GISTs ([@bib6]; [@bib11]).

Despite successful results in phase III trial, regorafenib prolongs PFS for only several months, indicating unmet medical needs for GIST patients refractory to multiple TKIs. Therefore, further clinical trials of new drugs are necessary, based on understanding the mechanisms of tumour resistance to TKIs. We found that dovitinib had modest activity against TKI-resistant GISTs. As 43% of our study cohort previously received nilotinib or regorafenib, the efficacy outcomes of dovitinib seem promising, encouraging its further clinical development in this indication. However, the target of dovitinib for clinical activity in GISTs remains unclear and further preclinical studies of dovitinib activity against primary and secondary KIT mutations are needed to understand its efficacy in TKI-resistant GISTs. Although dovitinib targets VEGFR and FGFR, the significance of VEGFR inhibition in GISTs after imatinib failure remains unknown ([@bib17]), and little is known about the role of the FGF pathway in treatment of GISTs. To address this issue, we are now conducting a correlative study of plasma protein biomarkers and plasma-based KIT mutations in this study cohort.

The dosing schedule of dovitinib tested in this study was tolerable and toxicities were generally mild. Most grade 3/4 toxicities were manageable by dose modification or supportive care, with only two patients discontinuing study treatment owing to toxicities. The dovitinib toxicities observed in this study were in line with those in patients with other types of cancer ([@bib31]; [@bib1]; [@bib20]; [@bib2]), with asthenia being the most common grade 3/4 AE (20% in the present study *vs* 15--27% in previous studies). In contrast with the rare haematological toxicities observed in previous trials ([@bib31]; [@bib20]; [@bib2]), 10% of our patients experienced grade 3/4 neutropenia and thrombocytopenia, although there were no complications.

Interim PET assessment after 4 weeks of treatment was found to predict PFS in these patients. Our findings agree with previous results, showing that PET is a sensitive tool to assess metabolic response to therapy in GISTs ([@bib29]). Furthermore, conventional tumour-size-based response criteria may have intrinsic limitations in patients with GIST, which may underestimate the benefits of TKIs ([@bib4]; [@bib30]). The use of PET in addition to conventional imaging may be helpful in differentiating 'true progression\' or 'true response\', especially in GIST patients with multiple lesions who progressed after several lines of treatment.

In line with previous results ([@bib20]; [@bib35]), we observed large interindividual variations in dovitinib exposure. As expected, exposure to dovitinib, as assessed by AUC, was about 28% higher on Week 4, Day 5 than on Week 1, Day 1 owing to drug accumulation resulting from multiple doses. Previous studies suggest that dovitinib exposure may be dependent on body weight, sex, renal dysfunction, and ethnicity ([@bib35]). Although all of our patients were Asian with low body weight (mean 62 kg), and 71% had impaired renal function, which may be associated with greater drug exposure ([@bib35]), the *C*~max~ and AUC of dovitinib in this study were consistent with those in patients with melanoma ([@bib20]) and even lower than those of patients with renal cell carcinoma ([@bib2]). Furthermore, we could not find any relationship between these potential covariates and dovitinib exposure in our patients. As the studies analysing pharmacokinetics of dovitinib, including ours, have all involved small sample size, these findings may be premature. Further efforts should be made to find the covariates affecting the blood level of dovitinib, and the relationship between dovitinib exposure and efficacy. These may be necessary for more effective clinical development of dovitinib.

In summary, dovitinib, a novel multikinase inhibitor that primarily targets VEGFR, FGFR, and KIT, showed modest antitumour activity in heavily pretreated patients with advanced GISTs. As this study reached its primary endpoint, further investigations of dovitinib are warranted in GIST patients.
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![**Waterfall plots of best per cent change in the sum of the longest tumour diameter by CT scan (**A**) and average SUV~max~ of all tumour lesions by PET scan (**B**).** Abbreviations: mPD=metabolic progressive disease; mPR=metabolic partial response; mSD=metabolic stable disease; PD=progressive disease; PR=partial response; SD=stable disease.](bjc2013594f1){#fig1}

![**CT (**A**) and PET (**B**) scan images of patients who achieved objective response.**](bjc2013594f2){#fig2}

![**Survival outcomes (**A**) and PFS by metabolic response after 4 weeks of dovitinib treatment (**B**).** In panel **A**, median PFS was 3.6 months (95% CI, 3.5--3.7) and median OS was 9.7 months (95% CI, 6.0--13.4). In panel **B**, median PFS was 2.8 months (95% CI, 0.7--4.9) in patients with mPD and 4.2 months (95% CI, 2.5--5.9; *P*=0.03) in patients with mPR or mSD. Abbreviations: mPD=metabolic progressive disease; mPR=metabolic partial response; mSD=metabolic stable disease; OS=overall survival; PFS=progression-free survival.](bjc2013594f3){#fig3}

###### Patient characteristics at baseline

  **Characteristics**                                **Overall (*****n*****=30)**
  -------------------------------------------------- ------------------------------
  Sex, male                                          21 (70%)
  Age (years), median (range)                        57.5 (35--76)
  **ECOG performance status**                        
  0--1                                               24 (80%)
  2--3                                               6 (20%)
  **Primary site**                                   
  Stomach                                            8 (27%)
  Small bowel                                        20 (67%)
  Others                                             2 (7%)
  **Metastatic site**                                
  Any                                                30 (100%)
  Peritoneum                                         22 (73%)
  Liver                                              20 (67%)
  Lung                                               4 (13%)
  Bone                                               4 (13%)
  **Kinase mutation (*n*=28)**                       
  *KIT* exon 11                                      20 (71%)
  *KIT* exon 9                                       5 (18%)
  *PDGFRA* exon 18                                   1 (4%)
  Wild type[a](#t1-fn2){ref-type="fn"}               2 (7%)
  **Documented disease progression on prior TKIs**   
  Imatinib                                           30 (100%)
  Sunitinib                                          28 (93%)
  TTP at imatinib 400 mg per day, median (range)     20.4 months (3.0--71.2)
  TTP at sunitinib, median (range)                   7.1 months (2.1--41.6)
  **Previous TKIs as third or more line therapy**    
  Nilotinib                                          8 (27%)
  Regorafenib                                        2 (7%)
  Both nilotinib and regorafenib                     3 (10%)

Abbreviations: ECOG=Eastern Cooperative Oncology Group; *PDGFRA=*platelet-derived growth factor receptor *α* TKI=tyrosine kinase inhibitor; TTP=time to progression.

No mutations in *KIT* exons 11, 9, 13, and 17, and *PDGFRA* exons 12 and 18.

###### Best response by RECIST 1.0 and metabolic response by PET

  **RECIST v1.0**                             **Total (*****n*****=30**[a](#t2-fn2){ref-type="fn"})
  ------------------------------------------- -------------------------------------------------------
  Partial response                            1 (3%)
  Stable disease[b](#t2-fn3){ref-type="fn"}   21 (70%)
  Progressive disease                         6 (20%)
  **Metabolic response by PET**               **Total (***n***=30**[a](#t2-fn2){ref-type="fn"})
  Partial response                            4 (13%)
  Stable disease                              15 (50%)
  Progressive disease                         9 (30%)

Abbreviation: PET=positron emission tomography.

Two patients were not evaluable due to early loss to follow-up.

Sustained for 8 weeks or more.

###### Adverse events occurring in ⩾10% of patients

                                           **Total (n=30)**                       
  ---------------------------------------- ------------------ --------- --------- --------
  Neutropenia[a](#t3-fn2){ref-type="fn"}   5 (20%)            2 (7%)    3 (10%)   1 (3%)
  Anaemia                                  10 (33%)           4 (13%)   1 (3%)    0 (0%)
  Thrombocytopenia                         10 (33%)           0 (0%)    1 (3%)    2 (7%)
  Anorexia                                 6 (20%)            4 (13%)   0 (0%)    0 (0%)
  Nausea                                   17 (57%)           1 (3%)    0 (0%)    0 (0%)
  Vomiting                                 9 (30%)            2 (7%)    1 (3%)    0 (0%)
  Dyspepsia                                5 (17%)            6 (20%)   0 (0%)    0 (0%)
  Stomatitis                               2 (7%)             5 (17%)   0 (0%)    0 (0%)
  Diarrhoea                                14 (47%)           3 (10%)   2 (7%)    0 (0%)
  Asthenia                                 9 (30%)            3 (10%)   6 (20%)   0 (0%)
  Skin rash                                7 (23%)            2 (7%)    0 (0%)    0 (0%)
  Elevation of AST                         10 (33%)           2 (7%)    0 (0%)    0 (0%)
  Elevation of ALT                         12 (40%)           2 (7%)    1 (3%)    0 (0%)
  Hyperbilirubinaemia                      2 (7%)             1 (3%)    0 (0%)    0 (0%)
  Increased creatinine                     3 (10%)            2 (7%)    0 (0%)    0 (0%)
  Hypertriglyceridaemia                    4 (13%)            1 (3%)    3 (10%)   0 (0%)
  Hypertension                             7 (23%)            4 (13%)   2 (7%)    0 (0%)
  Proteinuria                              3 (10%)            6 (20%)   1 (3%)    0 (0%)
  Headache                                 5 (17%)            1 (3%)    0 (0%)    0 (0%)
  Abdominal pain                           6 (20%)            6 (20%)   0 (0%)    0 (0%)

Abbreviations: AST=aspartate aminotransferase; ALT=alanine aminotransferase.

No patient had febrile neutropenia.
